Some fair questions Oaftar. Cutting circa 2/3 of headcount is...

Some fair questions Oaftar. Cutting circa 2/3 of headcount is undoubtedly unfortunate - particularly around Christmas time - however is likely necessary in order to stem cash outflows. We're seeing headcount reduction across businesses - even from companies at strength like Amazon.

Again, I'm perplexed as to why Director fees (including Dixon's compensation) has not been reduced further - it's been a common practice amongst companies experiencing tight conditions.

The upcoming JP Morgan Health Conference (Jan '23) could be a catalyst for further deal flow. One US-based Equity Research Analyst is expecting it to spur an uptick in the Biotech ETF (para-phrasing a Bloomberg article). It's important to note that across the board, Biotechs are close to multi-year lows, which is not necessarily reflective of advancements in fields like EV-based therapeutics. The potential of exosome medicines keeps me invested in Exopharm, however whether Exopharm can successfully execute remains an open question...